Abstract: ApolipoproteinE 4 (ApoE 4) has been linked to pathogenesis of Alzheimer's disease and has been suggested to be maintained through evolutionary pressure via a protective role in malaria infection. We evaluated Plasmodium falciparum viability at the intraerythrocyte stage by exposure to plasma from human subjects with ApoE 4/4 or ApoE 3/3. Plasma samples from ApoE 4/4 but not ApoE 3/3 donors inhibited growth and disrupted morphology of P. falciparum. Evolutionary history is characterized by war between pathogenic microorganisms and defense mechanisms countering their pathogenicities. ApoE 4 frequency is highest in sub-Saharan Africa and other isolated populations (e.g., Papua New Guinea) that exhibit endemic malaria. High ApoE frequency may off er selective advantage protecting against some infectious diseases (e.g., Plasmodium falciparum). These results implicate evolutionary pressure by malaria selecting humans with ApoE 4/4, even considering lower survival in late life. These selective advantages may be relevant in the exploration of possible disparities between Black and Whites in the incidence of Alzheimer's Disease.
A polipoprotein E (ApoE) has three major isoforms, ApoE 4, ApoE 3, and ApoE 2, that diff er from one another only by single amino acid substitutions. 1,2 ApoE 4 increases the risk of cardiovascular disease, atherosclerosis, and also is a major risk factor associated with 40-65% of cases of sporadic and familial Alzheimer's disease (AD). 3 Deleterious eff ects of ApoE 4 are not manifested until late in life. In contrast, if ApoE 4 provides even a minor protection against malaria or other infections in young persons until they reach their reproductive years, then the presence of the ApoE 4 gene will confer a selective advantage that would lead to its fi xation in the population, and thus could explain why the ApoE 4 gene is common among most populations. 1 These selective advantages may be relevant in the exploration of possible disparities between Black and Whites in the incidence of Alzheimer's Disease. [4] [5] [6] [7] The geographic and ethnic diff erences in the ApoE allele frequencies raise fascinating questions. In all populations, the ApoE 3 allele is the most frequent, with a range of 50%-90%, and the range of the ApoE 4 allele is about 5-35%. 1 In North American populations derived from Europe, the genotype E 4/4 is less than 1%; however, in the African subcontinent (sub-Saharan Africa) and certain other isolated populations, such as in Papua New Guinea, the frequency of the ApoE 4 allele is extremely high. [8] [9] [10] In these populations, the ApoE 4 allele might be increased due to a role in protection against infectious diseases.
11-13
A primary metabolic role for ApoE is to transport and deliver lipids from one tissue or cell type to another. 2, 14 During the erythrocyte cycle of Plasmodium falciparum parasite, there is a 500-700% increase in phospholipid levels in the infected erythrocyte and thus the parasite requires incorporation of intact phospholipids from the plasma. [15] [16] Compared with other ApoE isoforms, the ApoE 4 isoform is relatively ineff ective in encouraging neurite outgrowth, possibly due to less effi cient phospholipid transport. 17 There is evidence that ApoE plays a role in resistance to bacterial infections. The enhanced susceptibility of ApoE-null mice against Listeria monocytogenes, 18 and Klebsiella pneumoniae 19 has been reported. Additionally, there is evidence that ApoE plays a role in protection against malaria. The malaria circumsporozoite protein (CSP) utilizes the heparan sulfate proteoglycan (HSPG)/low density lipoprotein receptor-related protein (LRP) pathway to invade hepatocytes. Remnant lipoprotein, which use ApoE as the ligand and which interacts with the HSPG/LRP pathway, can inhibit host cell invasion of the CSP. 20 Malaria parasites have probably had a profound impact on recent human evolution. 21 This "malaria hypothesis" posits that certain hemoglobinopathies have been selected to high frequencies in particular populations because they protect against the eff ects of malaria infections. [22] [23] [24] [25] [26] Although these hemoglobinopathies are dangerous and oft en fatal, they sometimes confer an advantage in the form of protection against infectious diseases. 24, 25 This line of thinking leads us to hypothesize that apolipoproteins can play a role in the critical intraerythrocyte development stage of malaria and that if any one isoform has diff erent lipid carrying or transferring properties, it could interfere with disease progression.
In this study we directly test the eff ect of ApoE 4 on the growth of malaria parasites in red blood cells. Our fi ndings demonstrate ApoE 4 inhibits malaria parasite growth.
Methods

ApoE 3/3 and ApoE 4/4 donors. Approved by the University Hospitals-Case Medical
Center, Institutional Review Board. All subjects were adults. Each subject was assigned a unique ID number. To ensure confi dentiality, tubes of blood were labeled only with the ID number. All other subject information recorded for the study was kept in locked fi le cabinets, and/or password-protected computer databases. Both research assistants and investigators were blind to individual results. Vulnerable donors who had been infected with malaria or had taken anti-malarial drugs were not utilized in this experiment. To eliminate donors carrying any hemoglobinopathy and other red blood cell disorders, HbA genotype was determined by cellulose acetate and citrate agar electrophoresis and confi rmed by HPLC analysis. All donors carried normal HbAA and no red blood cell disorder. Seven ApoE 4/4 and six ApoE 3/3 donors were available in this project, and analyzed in various portions of the study and genotyped by standard molecular techniques. Related red blood cells were washed three times with medium and stored at 50% hematocrit in RPMI-1640 for up to four weeks at 4°C.
P. falciparum isolates. Nine diff erent P. falciparum parasite lines from a variety of geographical locations were evaluated in this study: 3D7, 1905 (PNG), Dd2 (Indochina), 11B3 (Honduras), FCB (Columbia), FCR3 (Gambia), FAB6 (South Africa), G134 (Ghana), and ItG2 (Southeast Asia).
In vitro parasite culture in ApoE 4/4 or ApoE 3/3 and growth experiment. Nine established P. falciparum lines from diff erent continents (see above) were maintained in HbAA human red cells collected from healthy blood bank donors. Parasites were cultured by the method of Trager and Jensen. 27 Albumax II (Gibco-BRL) was used instead of human serum. Parasite lines cultured in HbAA cells were enriched to 95% mature forms by Percoll-sorbitol methods. 28 The initial parasitemia were adjusted to 0.5% by using uninfected HbAA cells and cultured in complete medium containing 10% Apo E4/4 or E3/3 plasma from each donor. Culture media containing ApoE plasma were changed daily and parasite counts were determined by examination of Giemsa-stained blood smears. Parasitemia (mean ± SD) were calculated from triplicate counts of 2000 red cells. Serum ApoE 4/4 level and parasite growth inhibition. To determine whether the serum ApoE 4/4 levels are correlated with the parasite growth inhibition rate, we measured the serum ApoE 4/4 levels in each donor. Serum ApoE levels were determined, on coded samples without the knowledge of the donors, using standard methods. [29] [30] Electron microscopy. Nine P. falciparum lines were used in this experiment. Synchronized parasites were cultured in the ApoE 4/4 plasma from each donor or reconstituted ApoE 4/4 and processed for electron microscopy at the diff erent incubation time points (0, 3, 6, 12, and 24 hr), and morphology analyzed. [31] [32] [33] [34] [35] [36] [37] Morphological changes of the parasites incubated with ApoE 4/4 were compared with those cultured in normal plasma.
Results
We investigated 13 plasma samples (7 ApoE 4/4, 6 ApoE 3/3) from donors ( Figure 1A ). Six out of seven plasma samples from ApoE 4/4 donors inhibited the growth of P. falciparum. The one exception could be explained by the lower level of ApoE 4/4 in plasma (data not shown).
We tested the responses to one ApoE 4/4 plasma using four additional P. falciparum lines originating from a variety of geographical locations: Dd2 (Indochina), HB3 (Honduras), FCB (Columbia), FCR3 (Gambia). The tested ApoE 4/4 plasma inhibited the parasite growth of all P. falciparum lines ( Figure 1B) . ApoE 4/4 treatment led to parasite disintegration within intact RBC; parasite death was found at all stages of maturation. This result indicated that human ApoE 4/4 plasma could be a factor mediating malaria death (Figure 2) . The P. falciparum ItG2 line exhibited disorganization in vitro when grown in ApoE 4/4 plasmas. Condensation of cytoplasm, dilatation of plasma membrane, mitochondrial swelling, dilatation of cisternae of the rough endoplasmic reticulum, and the perinuclear space characterized parasite disintegration. The morphological changes suggested the target site of ApoE 4/4 in infected erythrocytes is diff erent from those of known anti-malarial drugs. Similar morphological changes observed in ApoE 4/4 plasma were not seen for malaria grown in ApoE 3/3 plasma (not shown).
Discussion
In this study, in vitro experiments showed that ApoE 4 but not ApoE 3 inhibits P. falciparum growth. These experiments provided the fi rst direct evidence that ApoE 4 plays a role in inhibition of P. falciparum. An interesting possible outcome of these studies is the key role ApoE 3 plays in parasite growth. ApoE 3 preferentially binds to the smaller, more phospholipid enriched high density lipoprotein, while ApoE 4 preferentially binds to the larger, triglyceride-rich very low density lipoproteins. These diff erences in lipoprotein association between ApoE 3 and ApoE 4 38 might be responsible for parasite growth inhibition. Three-dimensional structures of regions of Apo E highlight isoform diff erences. 39 For example, the critical rearrangement of the arginine 61 side chain alters the conformation of ApoE 4 and is probably responsible for several ApoE 4-specifi c roles. Identifi cation of the critical locus for the eff ect of Apo E 4 in the infected erythrocytes may aid development of new drugs for the treatment of P. falciparum malaria.
It seems there is a need for a critical balance between taking in fatty acids (from the plasma high-density lipoprotein (HDL) and losing red blood cell membrane cholesterol (to the plasma HDL) that is required for successful development and exit of parasites from the red blood cell. 40 The accumulation of fatty acids by malaria within the RBC is critical for development from the early invasion stage to the late invasion stage, peaking just before exit. This progression must be tightly regulated; otherwise too many fatty acids accumulate in the immediate vicinity of the infected RBC and parasite within. A prime example of why this progression and process of fatty acid uptake becomes critical is that more membrane will be needed to produce the multiple parasites from the one that originally invaded, just before RBC rupture and exit. That time, from early stage development to late stage development of parasites, seems to comprise the stages most aff ected by ApoE 4 in this study.
In summary, these fi ndings support the view that ApoE 4 persists in human populations in part due to protection from infection diseases. The increased frequency of ApoE 4 in some populations, e.g. Africans, is a direct result of evolutionary balance between protection from malaria and increased risk of mortality from a variety of degenerative diseases. This study supports the need for careful ethnobiological studies to uncover the molecular basis of health disparities. 
Notes
